These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Project Optimus seeks to transform how doses are selected and optimised in oncology drug development. As this initiative ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Detailed price information for Medpace Holdings Inc (MEDP-Q) from The Globe and Mail including charting and trades.

The company's backlog, which consists of anticipated future revenue from business awards, stood at $7.7 billion as of ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

BofA lowered the firm’s price target on Fortrea (FTRE) to $10 from $17 and keeps an Underperform rating on the shares after a Q4 miss and FY25 ...

Despite revenue declines, Fortrea Holdings Inc (FTRE) focuses on strengthening its backlog and enhancing customer satisfaction to drive future growth.

Ladies and gentlemen, thank you for standing by, and welcome to Fortrea fourth-quarter 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being ...

We reduced our fair value estimate to $15.50 per share from $27.20 to account for greater headwinds as a newly stand-alone company since its spinoff from Labcorp in 2023, which will weigh on revenue ...

Shares of Fortrea Holdings sank to a new low after the company said it expects revenue to drop this year. The stock fell 31% to a new all-time low of $9.55 in the first half of the trading day. The ...